Role of radiopharmaceuticals in the diagnosis and treatment of neuroendocrine tumours

European Journal of Cancer

Volumn 45, Issue SUPPL. 1, 2009, Pages 274-291

  Virgolini, Irene J ^a   Gabriel, Michael ^a   von Guggenberg, Elisabeth ^a   Putzer, Daniel ^a   Kendler, Dorota ^a   Decristoforo, Clemens ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 1 NAL3 OCTREOTIDE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO PHENYLALANINE TYROSINE OCTREOTIDE IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO PHENYLALANINE TYROSINE OCTREOTIDE Y 90; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LANREOTIDE IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LANREOTIDE Y 90; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID NAL3 OCTREOTIDE IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID NAL3 OCTREOTIDE LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE OCTREOTIDE GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE OCTREOTIDE IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE OCTREOTIDE LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE OCTREOTIDE Y 90; 1,4,8,11 TETRAAZACYCLOTETRADECANE N N' N'' N''' TETRAACETIC ACID OCTREOTIDE CU 64; CISPLATIN; FLUORO LEVO 3,4 DIHYDROXY PHENYLALANINE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; N ALPHA( 6 HYDRAZINONICOTINOYL) TYROSINE OCTREOTIDE TC 99M; OCTREOSAN; PENTETIC ACID DEXTRO PHENYLALANINE OCTREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; TECTROTYD; TOPOTECAN; UNCLASSIFIED DRUG; YTTRIUM 90;

ARTICLE; BONE MARROW TOXICITY; CARCINOID; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DOSIMETRY; DRUG DOSE ESCALATION; DRUG MEGADOSE; ERYTHROCYTE; HUMAN; IN VIVO STUDY; LIVER METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; PANCREAS CANCER; PARAGANGLIOMA; PATIENT SELECTION; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; TUMOR VOLUME; WORLD HEALTH ORGANIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; FORECASTING; HEMATOLOGIC DISEASES; HUMANS; KIDNEY FAILURE, CHRONIC; NEUROENDOCRINE TUMORS; PATIENT SELECTION; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; QUALITY OF LIFE; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RECEPTORS, PEPTIDE; RECEPTORS, SOMATOSTATIN; TREATMENT OUTCOME;

EID: 70349157203     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(09)70042-5     Document Type: Article

References (139)

1. ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors Part 1 and Part 2. Neuroendocrinology 84 (2006) 151-216 and 2008;87:1-64.
2. Modlin I.M., Oberg K., Chung D.C., et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9 (2008) 61-72
3. O'Toole D., Hentic O., Corcos O., and Ruzniewski P. Chemotherapy for gastro-enteropancreatic endocrine tumors. Neuroendocrinology 80 Suppl 1 (2004) 79-84
4. Arnold R, Müller H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. Gastrointestinal Cancer Symposium 2009, Abstract No. 121.
5. Kaltsas G., Rockall A., Papadogias D., Reznek R., and Grossman A.B. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrin 151 (2004) 15-27
6. Leboulleux S., Dromain C., Vataire A.L., et al. Prediciton and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: A prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 93 (2008) 3021-3028
7. 3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48 (2007) 508-518
8. Dromain C., de Baere T., Lumbroso J., et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 23 (2005) 70-78
9. Virgolini I., Yang Q., Li S., et al. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumour cell membrane receptors. Cancer Res 54 (1994) 690-700
10. Virgolini I., Pangerl T., Bischof C., Smith-Jones P., and Peck-Radosavljevic M. Somatostatin receptor subtype expression in human tissues: a prediction for diagnosis and treatment of cancer?. Eur J Clin Invest 27 (1997) 645-647
11. Cescato R., Schulz S., Waser B., et al. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med 47 (2006) 502-511
12. Liebow C., Reilly C., Serrano M., and Schally A. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci USA 86 (1989) 2003-2007
13. Schally A. Oncological applications of somatostatin analogues. Cancer Res 15 (1988) 6977-6985
14. Yamada Y., Post S., Wang K., Tager H., Bell G., and Seino S. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract and kidney. Proc Natl Acad Sci USA 89 (1992) 251-255
15. Yamada Y., Reisine T., Law S., et al. Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. Mol Endocrinol 6 (1992) 2136-2142
16. Yasuda K., Res-Domiano S., Breder C., et al. Cloning of a novel somatostatin receptor, SST3, coupled to adenylate cyclase. J Biol Chem 267 (1992) 20422-20428
17. Demchyschyn L., Srikant C., Sunahara R., et al. Cloning and expression of a human somatostatin-14-selective receptor variant (somatostatin receptor 4) located on chromosome 20. Mol Pharmacol 43 (1993) 894-901
18. Corness J., Demchyschyn L., and Seeman P. A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides. FEBS Lett 321 (1993) 279-284
19. Rohrer L., Raulf F., Bruns C., Buetter R., Hofstaedter F., and Schüle R. Cloning and characterization of a fourth human somatostatin receptor. Proc Natl Acad Sci USA 90 (1993) 4196-4200
20. Bell G.I., Yasada K., and Kong H. Molecular biology of somatostatin receptors. Ciba Found Symp 190 (1995) 65-88
21. Reubi J.C. In vitro identification of vasoactive peptide receptors in human tumours: implications for tumour imaging. J Nucl Med 36 (1995) 1846-1853
22. 111In-labelled DTPA-or DOTA-bombesin analogues for receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 43 (2002) 1650-1656
23. 90Yttrium for targeting bombesin receptor-expressing tumours. Cancer Res 64 (2004) 6707-6715
24. Henning I., Laissue J., Horisberger U., and Reubi J.C. Substance P receptors in human primary neoplasms: tumoural and vascular localisation. Int J Cancer 61 (1995) 786-792
25. Reubi J.C.C., Waser B., Friess H., Buchler M., and Laissue J. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut 42 (1998) 546-550
26. Reubi J.C., Schar J.C., Waser B., et al. Affinity profiles for human somatostatin receptor subtypes SST1-5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27 (2000) 273-282
27. Ginj M., Chen J., Walter M.A., Eltschinger V., Reubi J.C., and Maecke H.R. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res 11 (2005) 1136-1145
28. Antunes P., Ginji M., Zhang H., et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?. Eur J Nucl Med Mol Imaging 34 (2007) 982-993
29. 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol 7 (2006) 728-734
30. 1]-octreotide in humans. J Nucl Med 38 (1997) 103A
31. 1-octreotide. A case history. Ann NY Acad Sci 733 (1994) 496-504
32. Krenning E., Kooij P., Pauwels S., et al. Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion 57 (1996) 57-61
33. Otte A., Jermann E., Behe M., et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 24 (1997) 792-795
34. 90Yttrium labelled somatostatin-analogue for cancer treatment. Lancet 351 (1998) 417-418
35. 68Ga-DOTA-TOC: preliminary data. Eur J Nucl Med 12 (2001) 1751-1757
36. Smith-Jones P., Bischof C., Leimer M., et al. "MAURITIUS": a novel tumour diagnostic and therapeutic somatostatin analogue. Endocrinology 140 (1999) 5136-5148
37. 3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results. Eur J Nucl Med 29 (2002) 742-753
38. 3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun 19 (1998) 283-288
39. Wild D., Schmitt J.S., Ginj M., et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imag 30 (2003) 1338-1347
40. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumours. J Nucl Med 42 (2001) 213-221
41. 111In-labelled octreotide derivates. Eur J Nucl Med 27 (2000) 1318-1325
42. 3-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumours. QJ Nucl Med Mol Imag 49 (2005) 237-244
43. 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumours. J Nucl Med 44 (2003) 708-716
44. Virgolini I., Raderer M., Kurtaran A., et al. Vasoactive intestinal peptide (VIP) receptor imaging for the localisation of intestinal adenocarcinomas and endocrine tumours. N Engl J Med 331 (1994) 1116-1121
45. 123iodine-vasoactive intestinal peptide scintigraphy. J Nucl Med 39 (1998) 1575-1579
46. Virgolini I., Kurtaran A., Raderer M., et al. Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med 36 (1995) 1732-1739
47. 99mTc (I)-postlabelled high affinity bombesin analogue as a potential tumour imaging agent. Bioconjug 13 (2002) 599-604
48. Scopinaro F., Varvarigou A., Ussof W., et al. Technetium labelled bombesin-like peptide: preliminary report on breast cancer uptake in patients. Cancer Biother Radiopharm 17 (2002) 327-335
49. 111In-labelled DTPA-or DOTA-bombesin analogues for receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 43 (2002) 1650-1656
50. Behr T., Behe M., Angerstein C., et al. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Clin Cancer Res 5 (1999) 3124s-3138s
51. Behr T., and Behe M. Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med 32 (2002) 97-109
52. 99mTechnetium-RP527, a GRP analogue for visualisation of GRP receptor expressing malignancies: a feasibility study. Eur J Nucl Med 27 (2000) 1694-1699
53. Akilefu S., Srinivasan A., Schmidt M., Jimenez H., Bugaj J., and Erion J. Novel bioactive and stable neurotensin peptide analogue capable of delivering radiopharmaceuticals and molecular beacons to tumour. J Med Chem 46 (2003) 3403-3411
54. Garcia-Garayoa E., Allemann-Tannahill L., Blauenstein P., et al. In vitro and in vivo evaluation of new radiolabelled neurotensin(8-13) analogues with high affinity for NT1 receptors. Nucl Med Biol 28 (2001) 75-84
55. 99Tc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J Nucl Med 44 (2003) 1649-1654
56. van Hagen P., Breeman W., Reubi J.C., et al. Visualization of the thymus by substance P receptor scintigraphy in man. Eur J Nucl Med 23 (1996) 1508-1513
57. Gasnier B., Roisin M.P., Scherman D., Coornaert S., Desplanches G., and Henry J.P. Uptake of meta-iodobenzylguanidine by bovine chromaffin granule membranes. Mol Pharmacol 29 (1986) 275-280
58. Kaltsas G., Korbonits M., Heintz E., et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrin Metab 86 (2001) 895-902
59. Chrisoulidou A., Kaltsas G., Ilias I., and Grossman A. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocrine-Related Cancer 14 (2007) 569-585
60. 11C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrin Metab 90 (2005) 3392-3400
61. 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine-tumours. Eur J Nucl Med Mol Imaging 35 (2008) 1431-1438
62. 18F-DOPA) positron emission tomography as a tool to localize an insolinoma or b-cell hyperplasia in adult patients. J Clin Endocrin Metab 92 (2007) 1237-1244
63. 90Y-DOTATOC therapy. Eur j Nucl Med Mol Imaging 33 (2006) 1115-1122
64. 18F-FDG. Cancer 112 (2008) 2447-2455
65. Lamberts S., Bakker W., Reubi J.C., and Krenning E. Somatostatin receptor imaging in the localization of endocrine tumours. N Engl J Med 323 (1990) 1246-1249
66. Krenning E., Bakker W., Breeman W., et al. Localization of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1 (1989) 242-244
67. 1-OCT. Eur J Nucl Med 23 (1996) 1388-1399
68. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20 (1993) 716-731
69. Al-Nahhas A., Win Z., Szyszko T., Khan S., and Rubello D. What can gallium-68 PET add to receptor and molecular imaging?. Eur J Nucl Med Mol Imaging 34 (2007) 1897-1901
70. 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 33 (2006) 532-540
71. Virgolini I., Gabriel M., Putzer D., Kendler D., et al. Innsbruck experience with peptide related radionuclide therapie (PRRT) in patients with somatostatin receptor positive (SSTR) tumours: 1)Long-term follow-up of clinical response. World J Nucl Med 7 (2008) 274 5(A)
72. 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 34 (2007) 1617-1626
73. 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 34 (2007) 1617-1626
74. Baum R.P., Niesen A., Leonhardi J., Wortmann R., Müller D., and Rösch F. Receptor PET/CT imaging of neuroendocrine tumours using the Ga-68 labelled, high affinity somatostatin analogue DOTA-1-NaI3-octreotide (DOTA-NOC): Clinical Results in 327 patients. Eur J Nucl Med Mol Imaging 32 (2005) 54 5(A)
75. 3)octreotide: which peptide is preferable for PRRT?. Eur J Nucl Med Mol Imaging 33 (2006) 1346-1351
76. 18F-FDOPA. J Nucl Med Mol Imaging 45 (2004) 1161-1167
77. Modlin M., Latich I., Zikusoka M., Kidd M., Eick G., and Chan A. Gastrointestinal carcinoids: the evolution of diagnostic strategies. J Clin Gastroenterol 40 (2006) 752-782
78. 3]-octreotide. J Nucl Med 33 (1992) 652-658
79. 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 31 (2003) 1257-1262
80. 3-octreotate. J Nucl Med 46 Suppl 1 (2005) 83-91
81. 3-octreotide (SMT487)-a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimes of amino acid co-infusion. Eur J Nucl Med Mol Imag 30 (2003) 510-516
82. 0]octreotide: the Rotterdam experience. Sem Nucl Med 32 (2002) 110-122
83. 111Indium-pentreotide prologs survival in gastroenteropancreatic malignancies. Sem Nucl Med 32 (2002) 123-132
84. 111In-octreotide therapy in combination with radiosensitizing 5-FU chemotherapy for treatment of SSR-expressing neuroendocrine tumours. J Nucl Med 64 (2005) 437A
85. 90Yttrium DOTA-DOC; first clinical results. Eur J Nucl Med 26 (1999) 1439-1447
86. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 12 (2001) 941-945
87. 90Y-DOTATOC. J Nucl Med 43 (2002) 610-616
88. 90Yttrium-DOTA-DOC in neuroendocrine tumours?. Eur J Nucl Med 29 Suppl (2002) 100A
89. 3-octreotide; the experience of the European Institute of Oncology group. Semin Nucl Med 32 (2002) 141-147
90. 3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 66 (2002) 393-398
91. 90Y-DOTA-TOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imag 30 (2003) 207-216
92. Chinol M., Bodei L., Cremonesi M., and Paganelli G. Receptor-mediated radiotherapy with Y-DOTA-D-Phe-Tyr-octreotide: the experience of the European Institute of Oncology Group. Sem Nucl Med 32 (2002) 141-147
93. 3]-octreotide in patients with somatostatin receptor positive tumours. Eur J Nucl Med Mol Imag 30 Suppl 2 (2003) 232A
94. 90Y-SMT 487 in patients with neuroendocrine tumours. J Nucl Med 44 (2003) 1556-1560
95. 90DOTA-TATE) in patients with neuroendocrine tumours. J Nucl Med 45 Suppl (2004) 441A
96. http://nuklearmedizin.i-med.ac.at/
97. 3]octreotate in patients with endocrine gastroenteropancreatic tumours. J Clin Oncol 23 (2005) 2762
98. 177Lu-DOTA 0, Tyr 3] octreotate: toxicity, efficacy, and survival. J Clin Oncol 26 (2008) 2124-2130
99. 177Lu DOTA-NOC. Cancer Biother Radiopharm 22 (2007) 406-416
100. 90Y-DOTATOC. J Nucl Med 46 (2005) 1310-1316
101. 90Y-DOTA-TATE) in patients with metastatic neuroendocrine tumours. Eur J Nucl Med 31 Suppl 2 (2004) 155A
102. 68Ga-DOTA-NOC. J Nucl Med 64 (2005) 435A
103. Handkiewicz Junak D., Baum R.P., and Jarzak B. Toxicity of peptide receptor radiotherapy (PRRT) using the somatostatin analogue DOTA-NOC labelled with Y-90 or Lu-177. Eur J Nucl Med Mol Imag 32 Suppl 1 (2005) 202
104. 90Y-DOTA-Lanreotide: Results and implications of the MAURITIUS trial. Sem Nucl Med 32 (2002) 148-155
105. 90Yttrium-DOTA-lanreotide therapy. Cancer Biotherapy & Radiopharm 18 (2003) 276-277
106. 90Y-DOTA-lanreotide as effective palliative therapy. Radiology 237 (2005) 718-726
107. 68Ga-DOTA-lanreotide in tumour patients. Nuclear Medicine/Nuklearmedizin 44 (2005) 24A
108. 90Y-lanreotide. J Nucl Med 45 Suppl (2004) 446A
109. Rodrigues M., Gabriel M., Heute D., Putzer D., Griesmacher A., and Virgolini I. Concordance between results of somatostatin receptor scintigraphy with 111In-DOTA-DPhe 1-Tyr 3-octreotide and chromogranin A assay in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 35 (2008) 1796-1802
110. Aaronson N., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30; A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993) 365-376
111. 3]octreotate. J Clin Oncol 22 (2004) 2724-2728
112. 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 35 (2008) 1847-1856
113. Kwekkeboom D., Mueller-Brand J., Paganelli G., et al. Overview of results of peptide receptor radionuclid therapy with 3 radiolabelled somatostatin analogues. J Nucl Med 46 Suppl 1 (2005) 62-66
114. Reubi J.C. Targeting CCK receptors in human cancers. Curr Top Med Chem 7 (2007) 1239-1242
115. Behr T.M., Jenner N., Radetzky S., et al. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med 25 (1998) 424-430
116. a-His)acetic acic-modified [D-Glu1]-minigastrin. Bioconjug Chem 15 (2004) 864-871
117. 99mTc-labeled minigastrin analogs. J Nucl Med 46 (2005) 1727-1736
118. Béhé M., and Behr T.M. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers 66 (2002) 399-418
119. Béhé M., Kluge G., Becker W., Gotthardt M., and Behr T.M. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med 46 (2005) 1012-1015
120. 99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours. Eur J Nucl Med Mol Imaging 34 (2007) 1209-1218
121. Good S., Walter M.A., Waser B., et al. Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours. Eur J Nucl Med Mol Imaging 35 (2008) 1868-1877
122. 111In-labelled minigastrin. Eur J Nucl Med Mol Imaging 35 (2008) 386-392
123. Gotthardt M., Béhé M.P., Beuter D., et al. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 33 (2006) 1273-1279
124. Gotthardt M., Béhé M.P., Grass J., et al. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Endocr Relat Cancer 13 (2006) 1203-1211
125. Hoefnagel C.A., Voute P.A., de Kraker J., et al. Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. J Nucl Med 28 (1987) 308-314
126. 131I-MIBG Therapies in patients with primary resistant high-risk neuroblastoma: preliminary results. Cancer Biother Radiopharm 22 (2007) 105-112
127. Matthay K.K., Panina C., Huberty J., et al. correlation of tumor and whole body dosimetry with tumor response and toxicity in refractory neuroblastoma with 131 I-mIBG. J Nucl Med 42 (2001) 1713-1721
128. 131I]-metaiodobenzylguanidine and topotecan combination treatment of tumors expressing the noradreanaline transporter. Clin Cancer Res 11 (2005) 7929-7937
129. Gaze M.N., Chang Y., Flux G.D., et al. Feasibility of dosimetry-based high-dose 131-metaiodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 20 (2005) 195-199
130. Scholz T., Eisenhofer G., Pacak K., Dralle H., and Lehnert H. Current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 92 (2007) 1217-1225
131. 3-Octreotide (DOTATOC) for treating neuroendocrine tumours. J Nucl Med 65 (2005) 1449A
132. Yanik G.A., Levine J.E., Matthay K.K., et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 20 (2002) 2142-2149
133. Yao J.C., Zhang J.X., Rashid A., et al. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res 13 (2007) 234-240
134. Faivre S., Delbaldo C., Vera K., et al. Safety pharmacokinetic and antiumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24 (2006) 25-35
135. Duran I., Kortmansky J., Singh D., et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95 (2006) 1148-1154
136. Fueger B., Hamilton G., Raderer M., et al. Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumour cells. J Nucl Med 42 (2001) 1856-1862
137. Kulke M.H., Stuart K., Enzinger P.C., et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24 (2006) 401-406
138. Kulke M.H., Wu B., Ryan D.P., et al. A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci 51 (2006) 1033-1038
139. 177Lu-octreotate in combination with capecitabine in seven patients with gastroeenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 35 (2008) 743-748